Industry News
Cancer-linked protein helps control fate of intestinal stem cells
3/12/2015
An international group of researchers has shown that a regulatory protein involved in controlling how cancer spreads through the body also influences the fate of stem cells in the intestine of mice.
What's your genetic destiny? More than half of parents want to know disease risks
3/12/2015
85 percent of parents had identical interest for selves and childrenWould you want to know if you or your children had risk of hereditary cancer, a genetic risk for cardiovascular disease or...
Radiation plus ipilimumab shrank tumors in some patients, but preclinical data suggests adding second immunotherapy will elicit response in resistant patientsTreating metastatic melanoma with a...
African-American cancer patients' depression symptoms under-recognized, CWRU study finds
3/12/2015
Case Western Reserve University nurse scientist Amy Zhang, who has long examined quality-of-life issues in cancer patients, wondered whether depression in African-American cancer patients has been...
Fifteen new breast cancer genetic risk 'hot-spots' revealed
3/12/2015
Scientists have discovered another 15 genetic 'hot-spots' that can increase a woman's risk of developing breast cancer, according to research published in Nature Genetics.
Patients in England and Wales with chronic lymphocytic leukaemia (CLL) could soon benefit from Gazyvaro, after the National Institute for Health and Care Excellence (NICE) issued a positive Final...
Understanding of cell enzyme flipped on its head
3/11/2015
Researchers from Manchester, working with scientists in California, have found that certain molecules long thought to promote cancer growth, in fact suppress tumours, suggesting that therapeutic...
Apple and Sage Bionetworks, together with UCLA cancer research pioneer and collaborator Dr.
Patients in Scotland with a rare and life-threatening blood cancer now have access to Jakavi® (ruxolitinib), the only licensed oral treatment for enlarged spleen or the symptoms related to...
Advanced thyroid cancer responds to targeted therapy with sunitinib
3/11/2015
In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity, a new phase 2 clinical trial has found.